1
|
Ziani PR, de Bastiani MA, Scotton E, da Rosa PH, Schons T, Mezzomo G, de Carvalho Q, Kapczinski F, Rosa AR. Drug Repurposing and Personalized Treatment Strategies for Bipolar Disorder Using Transcriptomic. Braz J Psychiatry 2024. [PMID: 38446713 DOI: 10.47626/1516-4446-2023-3441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 01/10/2024] [Indexed: 03/08/2024]
Abstract
OBJECTIVE The present study combined transcriptomic data and computational techniques based on gene expression signatures to identify novel bioactive compounds or FDA-approved drugs for the management of Bipolar Disorder (BD). METHODS Five transcriptomic datasets, comprising a total of 165 blood samples from BD case-control, were selected from the Gene Expression Omnibus repository (GEO). The number of subjects varied from 6 to 60, with a mean age ranging from 35 to 48, with a gender variation between them. Most of the patients were on pharmacological treatment. Master Regulator Analysis (MRA) and Gene Set Enrichment Analysis (GSEA) were performed to identify statistically significant genes between BD and HC and their association with the mood states of BD. Additionally, existing molecules with the potential to reverse the transcriptomic profiles of disease-altered regulons in BD were identified using the LINCS and cMap databases. RESULTS MRA identified 59 potential MRs candidates modulating the regulatory units enriched with genes altered in BD, while the GSEA identified 134 enriched genes, and a total of 982 regulons had their activation state determined. Both analyses showed genes exclusively associated with mania, depression, or euthymia, and some genes were common between the three mood states. We identified bioactive compounds and licensed drug candidates, including antihypertensives and antineoplastics, as promising candidates for treating BD. Nevertheless, experimental validation is essential to authenticate these findings in subsequent studies. CONCLUSION Although preliminary, our data provides some insights regarding the biological patterns of BD into distinct mood states and potential therapeutic targets. The combined transcriptomic and bioinformatics strategy offers a route to advance drug discovery and personalized medicine by tapping into gene expression information.
Collapse
Affiliation(s)
- Paola Rampelotto Ziani
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Marco Antônio de Bastiani
- Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Ellen Scotton
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Pedro Henrique da Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Tainá Schons
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil
| | - Giovana Mezzomo
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Quênia de Carvalho
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Flávio Kapczinski
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Department of Psychiatry, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil. National Institute of Translational Science and Technology in Medicine, Porto Alegre, RS, Brazil. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada
| | - Adriane R Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil. Department of Pharmacology, Institute of Basic Science Health, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| |
Collapse
|